Baker Bros. Capital (GP), LLC
CIK 1244390 · last filed 2012-01-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IDP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
21ST FLOOR
NEW YORK, NY 10065
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Seagen Inc. (SGEN) Delisted | Director | 539,130 | $228.74 | $123.32M | $119.4K | 3 | 2012-01-04 |
| BCRX | 10%+ Owner | 62,407 | $7.88 | $491.8K | $0 | 1 | 2011-07-05 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 194,415 | — | — | $9.4K | 2 | 2011-06-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 105,694 | — | — | -$428.5K | 2 | 2009-05-20 |
| INCY | Director | 284,025 | $113.31 | $32.18M | $46.2K | 4 | 2008-12-22 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 387 | $7.22 | $2.8K | -$75.2K | 1 | 2008-07-16 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | 10%+ Owner | 163,256 | — | — | $81.8K | 2 | 2008-05-30 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 95,563 | — | — | -$479.6K | 2 | 2007-12-07 |
Recent Filings · Page 2 of 2
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-01-31 | INCY | Buy (P) | — | $0 | EDGAR |
| 2007-12-21 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Buy (P) | +6,177 | $81.8K | EDGAR |
| 2007-12-19 | INCY | Buy (P) | +1,296 | $13.7K | EDGAR |
| 2007-12-12 | INCY | Buy (P) | +2,366 | $23.6K | EDGAR |
| 2007-12-07 | Aceragen, Inc. (IDP) Delisted | Sell (S) | −13,131 | -$161.7K | EDGAR |
| 2007-10-31 | Aceragen, Inc. (IDP) Delisted | Sell (S) | −26,259 | -$317.9K | EDGAR |
| 2007-05-21 | GENOMIC HEALTH INC (GHDX) Delisted | Other (J) | +5,409 | $83.8K | EDGAR |
| 2007-04-17 | VIROPHARMA INC (VPHM) Delisted | Sell (S) | −28,029 | -$430.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.